These abstracts are presented in alphabetical order according to the name of the first author.

**CLINICAL POSTERS**

**POSTER 38**: Second generation tkis in frontline management of chronic myeloid leukemia are associated with fewer events than imatinib: a real world experience in colombia  
*Virginia Abello, Maria Helena Solano, Licet Villamizar, Daniel Espinosa, Claudia Casas*

**POSTER 39**: Validation of the MD anderson symptom inventory for CML (MDASI-CML) for Asian CML patients treated with imatinib  
*Jinyi Cao, Xiaohui Xin, Charles Chuah, Edmund Teo*

**POSTER 40**: Development of a sample preparation protocol for GBMHM external quality assessment for quantification of BCR-ABL1 transcripts using Xpert® BCR-ABL ultra  
*Jean-Michel Cayuela, Gwo-Jen Day, Carole Maute, Krupa Shridhar*

**POSTER 41**: Evaluation of 10-year imatinib’s treatment effects on chronic myeloid leukemia patients in chronic phase  
*Dung Co, Dung Phu, Hoa Nguyen, Nguyen Thanh*

**POSTER 42**: Chronic myeloid leukemia with e19a2 BCR-ABL1 transcript: a case report  
*Daniela Coelho, Dino Andrade Luís, Raquel Guilherme, Leticia Ribeiro*

**POSTER 43**: Sokal, hasford and EUTOS scores - predictive value in the tki’s era, retrospective analysis of single center cohort  
*Catarina Dantas Rodrigues, Conceição Constanço, Paula Rocha, Maria Reis, Helena Silva*

**POSTER 44**: Evaluation of Xpert® BCR-ABL ultra using different external quality assessment reference materials  
*Gwo-Jen Day, Carole Maute, Alba Levitas, Stuart Scott, Sandy Huang, Wendy Wong, Jean-Michel Cayuela, Krupa Shridhar, Michael Bates, Annie Tapley, Rachel Blackman, Brian Rhee*

**POSTER 45**: Concurrent or sequential diagnosis of chronic myeloid leukemia and myeloproliferative neoplasm: report of four cases  
*Daniela Giovanna De Ritis, Silvia Betti, Francesco Autore, Patrizia Chiusolo, Valeria De Stefano, Sara Marietti, Elena Rossi, Simona Sica, Federica Sorà*
POSTER 46: Xpert® BCR-ABL ultra, a high sensitivity assay with a limit of detection reaching MR4.5 and below on an international reporting scale
Marina Deschamps, Geoffrey Uy, Wendy Wong, Huilin Wei, Julie Woolworth, Natalie Wu, Jacqueline Payton, Aaron Bossler, Christophe Ferrand, Michael Bates, Chris Lykke, Gerald Feldman, Krupa Shridhar, Christina Lockwood, Brian Rhee, Gwo-Jen Day, Alice Mims, Sandy Huang, Charles Schiffer, Alba Levitas

POSTER 47: Patient information and comprehension in CML: opportunities for improvement through the cmylife web-based e-health platform
Geneviève Ector, Jeroen J. Janssen, Marieke Nowee, Rosella Hermens, Peter E. Westerweel, Nicole Blijlevens

POSTER 48: Coincidence of chronic myeloid leukemia and multiple myeloma: a case report
Edgar Faber, Jana Homolová, Petra Krhovska, David Starostka, Tomáš Papajík, Hana Urbánková, Ivana Skoumalová, Tomáš Szotkowski, Martina Divoká, Lucia Vrábolová

POSTER 49: Tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia: a retrospective analysis of 293 Italian patients
Carmen Fava, Giovanna Rege-Cambrin, Irene Dogliotti, Paola Berchialla, Marco Cerrano, Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, Bruno Martino, Carlo Gambacorti-Passerini, Elisabetta Abruzzese, Ester Orlandi, Elena Chiara, Patrizia Pregno, Antonella Gozzini, Paolo Avanzini, Micaela Bergamaschi, Monica Crugnola, Monica Bocchia, Sara Galimberti, Davide Ravezzi, Alessandra Iurlo, Daniele Cattaneo, Roberto Latagliata, Massimo Breccia, Michele Ceredone, Marco Santoro, Mario Annunziata, Luciano Levato, Fabio Stagno, Francesco Cavazzini, Nicola Sgherza, Gioacchino Catania, Luigi Luciano, Sabina Russo, Pellegrino Musto, Giovanni Caacci, Federica Sorà, Francesco Iuliano, Francesca Lunghi, Giorgina Specchia, Michele Baccarani, Dario Ferrero, Giuseppe Saglio

POSTER 50: Imatinib mesylate for first-line therapy of chronic phase chronic myelogenous leukemia patients in the long-term
Gaelle Fossard, François-Xavier Mahon, Vincent Alcazer, Pierre Sujobert, Franck E. Nicolini, Isabelle Tigaud, Mohamed Sobh, Gabriel Etienne, Stephane Morisset, Stéphanie Dulouca, Pascale Cony-Makhoul, Audrey Bidet

POSTER 51: Rebound basophilia during cytoreduction – an additional simple tool how to identify CML patients at risk?
Tomáš Fürst, Edgar Faber, Lucie Benešová, Hana Urbánková, Karel Indrák, Ivana Skoumalová, Lucia Vrábolová, Barbora Maiwaldová, Peter Rohoň, Martina Divoká

POSTER 52: Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia: 12-month patient-reported outcomes from the BFORE trial
Carlo Gambacorti-Passerini, Valentin Garcia-Gutierrez, Andreas Hochhaus, Nataliia Glushko, Carla Mamolo, Charles Chuah, Rocco Crescenzo, Jorge E. Cortes, Nathalie Bardy-Bouxin, Michael Mauro, Iryna Dyagil, Philipp le Coutre, Allison Jeynes-Ellis, Arlene Reisman, Michael Deininger, Tim H. Brümmendorf, Dong-Wook Kim, Dragana Milajkovic
POSTER 53: Comparative analysis of molecular kinetics after the first and second imatinib discontinuation
Jae Joon Han, Sung-Eun Lee, Soo Young Choi, Hye-Young Song, Soo-Hyun Kim, Mi-Yeon Choi, Joon Seong Park, Hyeoung-Joon Kim, Sung-Hyun Kim, Dae Young Zang, Sukjoong Oh, Yunseok Choi, Young Rok Do, Jae-Yong Kwak, Jeong-A Kim, Kyoo-Hyung Lee, Yeung-Chul Mun, Won Sik Lee, Myung Hee Jang, Jinny Park, Ji-Hyun Kwon, Dong-Wook Kim

POSTER 54: Validation of the EUTOS long term survival (ELTS) score in Dutch CML-patients
Jeroen J. Janssen, Otto Visser, Peter E. Westerweel, Jan J. Cornelissen, Inge G.P. Geelen, Noortje Thielen, Mels Hoogendoorn

POSTER 55: Clinical and immunological effects of nilotinib in combination with pegylated interferon-α2b in patients with suboptimal molecular response on imatinib (NordDutchCML009)

POSTER 56: Real world eligibility for treatment free remission in chronic myeloid leukemia patients-report from a tertiary cancer center in India
Sadhana Kannan, Hasmukh Jain, Manju Sengar, Tanmoy Mandal, Anant Gokarn, Navin Khattry, Bhausaheb Bagal, Sachin Punatar

POSTER 57: Quality of life (QOL) in patients with CML: questionnaire based study
Sung-Hyun Kim, Joon Seong Park, Yeo-Kyeoung Kim, Eun-Ji Choi, Inho Kim, Young-Uk Cho, Kyoung Ha Kim, Jeongok Lee, Hyewon Lee, Sang Kyun Sohn, Jun-Won Cheong, Chul Won Jung

POSTER 58: Quantitative estimation of BCR-ABL1 fusion gene RNA in patients of chronic myeloid leukemia (CML) undergoing treatment with tyrosine kinase inhibitors
Saqib Korejo

POSTER 59: Optimal whole blood storage conditions for measuring BCR-ABL1 accurately in Xpert® BCR-ABL ultra
Alba Levitas, Wendy Wong, Sandy Huang, Krupa Shridhar, Christophe Ferrand, Jerald Radich, Gwo-Jen Day, Marina Deschamps, Michael Bates, Brian Rhee

POSTER 60: Number-needed-to-treat (NNT) and cost of responses achieved in tyrosine kinase inhibitor (TKI) treatment of refractory chronic-phase chronic myeloid leukemia (CP-CML) in the United States (US)
Moshe Y. Levy, Lisa McGarry, Sergio Iannazzo, Hui Huang, Silvia Chirol
Presenter: Thihan Padukkavidana

POSTER 61: Systems medicine for CML – opportunities, benefits, and limitations
Hernik Liebscher, Katja Hoffmann, Ingo Roeder, Christoph Baldow, Matthias Kuhn, Katja Tampe, Ingmar Glauche
POSTER 62: Validation of a complete solution for BCR-ABL1 monitoring of both major and minor breakpoingts that reports ABL1 copy number
Keri Masson, Bernard Andruss, Stela Filipovic-Sadic, Marie Fahey, Justin Brown, Ion Beldorth, John Hedges, Michael Dodge

POSTER 63: Survival outcomes in patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving third- or subsequent line (3L) treatment
Daniel Stellato, Lisa McGarry, Hui Huang, Shaina Hastings, Thomas Delea, Jeffrey H. Lipton
Presenter: Thiathan Padukkavidana

POSTER 64: Stop tyrosine kinase inhibitors: experience of a clinical center
Patricia Seabra, Vanessa Mesquita, Mafalda Castro, Cristina Gonçalves, Luciana Xavier, Alexandra Mota, Luciana Pinho, Jorge Coutinho

POSTER 65: Expanding access to the quantideX® qPCR BCR-ABL I.S. Monitoring assay through deployment on multiple quantitative real-time instruments
John Milligan, Keri Masson, Ion Beldorth, John Hedges, Stephanie Borel, Justin Brown, Marie Fahey

POSTER 66: Long term outcomes of chronic myeloid leukemia patients treated with generic and innovator imatinib-report from a tertiary cancer center in India
Sachin Punatar, Navin Khattry, Tanmoy Mandal, Manju Sengar, Bhausheb Bagal, Hasmukh Jain, Anant Gokarn

POSTER 67: A case of chronic myeloid Leukemia (CML) with co-expression of the p210 BCR-ABL and p195 BCR-ABL
Patrícia Ribeiro, Madalena Silva, Alexandra Fernandes, Filipa Saraiva, Susana Gonçalves Pereira, Alexandra Lourenço, Raquel Vinhas, Luís Monteiro, Susana Costa Santos, Pedro Viana Batista

POSTER 68: Very early molecular response (VEMR) with frontline dasatinib treatment is a strong predictor of long-term BCR-ABL1 transcript levels in chronic myeloid leukemia patients: PCR-depth observational study
Young Rok Do, Won Sik Lee, Hawk Kim, Dong-Wook Kim, Jee Hyun Kong, Hyeoung-Joon Kim, Sung-Hyun Kim, Suk Joong Oh, Jae-Yong Kwak, Yeung-Chul Mun, Dae Young Zang, Jeong-A Kim, Soo Young Choi, Sung-Eun Lee, Youngwoong Won, Mi-Yeon Choi, Soo-Hyun Kim

POSTER 69: Successful treatment of chronic myeloid leukaemia in an 6-months old infant with imatinib
Adriana Roque, Sónia Silva, Joana Diamond, Isabelina Ferreira, Manuel João Brito

POSTER 70: Sustained complete molecular response with low dose dasatinib in a patient with blastic phase CML
Ioana Rus

POSTER 71: Thyroid dysfunction in BCR-ABL positive chronic myeloid leukemia patients treated with tyrosine kinase inhibitors and interferon alpha
Lenka Ruzickova, Patrícia Couceiro, Paulo Rodrigues-Santos, Paulo Freitas-Tavares, Jani Sofia Almeida
POSTER 72: Distribution of HLA class I and II alleles in Kazakh patients with chronic myeloid leukemia
Arailym Sarsembayeva, Indira Ramilyeva, Aida Turganbekova, Saniya Abdrakhmanova, Dana Baimukasheva, Eugene Zhiburt, Zhandos Burkibayev

POSTER 73: Socal score and its association with out comes of pregnancy in chronic myeloid leukemia patients who actively taking imatinib at conception and pregnancy
Ali Sheikh

POSTER 74: Hemophagocytic syndrome secondary to atypical chronic myeloid leukemia - case report of a rare association
Candido Silva, Paula Santos, Filipa Mousinho, Martinha Chorão, Tatiana Mendes, Lima Fernando

POSTER 75: Application of elts score in patients affected by chronic myeloid leukemia in comparison to sokal, hasford and EUTOS score
Federica Sorà, Nicola Piccirillo, Luca Laurenti, Simona Sica, Patrizia Chiusolo, Francesco Autore, Jolanda Bayer

POSTER 76: A phase I study of ruxolitinib plus nilotinib in chronic phase CML patients with molecular evidence of disease
Kendra Sweet, Lori Hazlehurst, Eva Sahakian, John Powers, Lisa Rodzon, Fadi Kayali, Kelly Hyland, Ashley Nelson, Javier Pinilla-Ibarz

POSTER 77: Determine the clinical and biologic features and evaluate the effect of treatment in children with chronic myeloid leukemia
Nguyen Thanh, Nghia Huynh

POSTER 78: Age-related somatic mutations and the ESC-score predict the occurrence of vascular adverse events in CML patients treated with nilotinib
Peter Valent, Bernd Jilma, Susanne Herndloher, Emir Hadzijusufovic, Gerit Holger Schernthaner, Gregor Hoermann, Wolfgang R. Sperr

POSTER 79: Evaluation of the effectiveness, safety and compliance of nilotinib in the treatment of newly-diagnosed CML patients in a “real-life” setting — preliminary results of the piano-CML study
Sara Valle, Alexandra Mota, Ana Macedo, Gonçalo Caetano, Ana Girio, Ana Saraiva, Joana Martins, Henrique Coelho, Manuel Cunha, Rui Magalhães, Conceição Lopes, Blanca Polo, Sónia Matos, João Rodrigues, Paula Santos, Renata Cabral, Ana Montalvao, Maria Joao Santos, Lurdes Guerra, Nuno Cerveira, Teresa Melo

POSTER 80: Discontinuation of tyrosine kinase inhibitors in Portuguese CML patients: a single institute experience
POSTER 81: Treatment response in patients with chronic myeloid leukemia on imatinib mesylate in Nairobi; Kenya
Robert Yatich

POSTER 82: Adverse effects of nilotinib and dasatinib on glycolipid metabolism compared with imatinib in persons with chronic myeloid leukemia in the chronic phase
Lu Yu, Qian Jiang, Robert Peter Gale